127 related articles for article (PubMed ID: 22419857)
1. Comparison of the effect between pegaptanib and ranibizumab on exudative age-related macular degeneration with small lesion size.
Nishimura Y; Taguchi M; Nagai T; Fujihara M; Honda S; Uenishi M
Clin Ophthalmol; 2012; 6():365-8. PubMed ID: 22419857
[TBL] [Abstract][Full Text] [Related]
2. Effect of switching therapy to pegaptanib in eyes with the persistent cases of exudative age-related macular degeneration.
Shiragami C; Ono A; Kobayashi M; Manabe S; Yamashita A; Shiraga F
Medicine (Baltimore); 2014 Oct; 93(18):e116. PubMed ID: 25319441
[TBL] [Abstract][Full Text] [Related]
3. Variable response of vascularized pigment epithelial detachments to ranibizumab based on lesion subtypes, including polypoidal choroidal vasculopathy.
Inoue M; Arakawa A; Yamane S; Kadonosono K
Retina; 2013 May; 33(5):990-7. PubMed ID: 23446653
[TBL] [Abstract][Full Text] [Related]
4. One-year results of photodynamic therapy combined with intravitreal ranibizumab for exudative age-related macular degeneration.
Nakamura T; Miyakoshi A; Fujita K; Yunoki T; Mitarai K; Yanagisawa S; Fuchizawa C; Hayashi A
J Ophthalmol; 2012; 2012():154659. PubMed ID: 22174997
[TBL] [Abstract][Full Text] [Related]
5. Initial non-responders to ranibizumab in the treatment of age-related macular degeneration (AMD).
Otsuji T; Nagai Y; Sho K; Tsumura A; Koike N; Tsuda M; Nishimura T; Takahashi K
Clin Ophthalmol; 2013; 7():1487-90. PubMed ID: 23901256
[TBL] [Abstract][Full Text] [Related]
6. Five-year treatment outcomes following intravitreal ranibizumab injections for neovascular age-related macular degeneration in Japanese patients.
Wada I; Oshima Y; Shiose S; Kano K; Nakao S; Kaizu Y; Yoshida S; Ishibashi T; Sonoda KH
Graefes Arch Clin Exp Ophthalmol; 2019 Jul; 257(7):1411-1418. PubMed ID: 31119425
[TBL] [Abstract][Full Text] [Related]
7. Early visual impacts of optical coherence tomographic parameters in patients with age-related macular degeneration following the first versus repeated ranibizumab injection.
Sayed KM; Naito T; Nagasawa T; Katome T; Mitamura Y
Graefes Arch Clin Exp Ophthalmol; 2011 Oct; 249(10):1449-58. PubMed ID: 21494878
[TBL] [Abstract][Full Text] [Related]
8. Comparison of Time to Retreatment and Visual Function Between Ranibizumab and Aflibercept in Age-Related Macular Degeneration.
Inoue M; Yamane S; Sato S; Sakamaki K; Arakawa A; Kadonosono K
Am J Ophthalmol; 2016 Sep; 169():95-103. PubMed ID: 27320059
[TBL] [Abstract][Full Text] [Related]
9. Change in choroidal thickness after intravitreal injection for treatment of neovascular age-related macular degeneration: Ranibizumab versus aflibercept.
Kaya F
J Fr Ophtalmol; 2017 Dec; 40(10):832-838. PubMed ID: 29113742
[TBL] [Abstract][Full Text] [Related]
10. The association of exudation pattern with anatomical and functional outcomes in patients with Neovascular Age-Related Macular Degeneration.
Inan S; Polat O; Karadas M; Inan UU
Rom J Ophthalmol; 2019; 63(3):238-244. PubMed ID: 31687625
[No Abstract] [Full Text] [Related]
11. Gas-mediated vitreomacular adhesion release with intravitral ranibizumab injections for exudative age-related macular degeneration.
Kang HM; Lee SJ; Kim CG; Chung EJ; Koh HJ
Graefes Arch Clin Exp Ophthalmol; 2016 Sep; 254(9):1681-92. PubMed ID: 26743753
[TBL] [Abstract][Full Text] [Related]
12. Intravitreal anti-VEGF injections for treating wet age-related macular degeneration: a systematic review and meta-analysis.
Ba J; Peng RS; Xu D; Li YH; Shi H; Wang Q; Yu J
Drug Des Devel Ther; 2015; 9():5397-405. PubMed ID: 26451092
[TBL] [Abstract][Full Text] [Related]
13. Early responses to intravitreal ranibizumab in typical neovascular age-related macular degeneration and polypoidal choroidal vasculopathy.
Matsumiya W; Honda S; Bessho H; Kusuhara S; Tsukahara Y; Negi A
J Ophthalmol; 2011; 2011():742020. PubMed ID: 21772985
[TBL] [Abstract][Full Text] [Related]
14. Intravitreal aflibercept for ranibizumab-resistant exudative age-related macular degeneration with choroidal vascular hyperpermeability.
Nomura Y; Yanagi Y
Jpn J Ophthalmol; 2015 Jul; 59(4):261-5. PubMed ID: 25983109
[TBL] [Abstract][Full Text] [Related]
15. Comparison of clinical efficacy of intravitreal ranibizumab with and without triamcinolone acetonide in macular edema secondary to central retinal vein occlusion.
Fan C; Wang Y; Ji Q; Zhao B; Xie J
Curr Eye Res; 2014 Sep; 39(9):938-43. PubMed ID: 24635755
[TBL] [Abstract][Full Text] [Related]
16. Intravitreal triamcinolone, bevacizumab and pegaptanib for occult choroidal neovascularization.
Forte R; Cennamo G; Finelli M; Cesarano I; D'Amico G; De Crecchio G; Cennamo G
Acta Ophthalmol; 2010 Dec; 88(8):e305-10. PubMed ID: 20946332
[TBL] [Abstract][Full Text] [Related]
17. Comparison of 2-Year Outcomes between Intravitreal Ranibizumab and Intravitreal Aflibercept for Diabetic Macular Edema with "Treat-and-Extend" Regimen-Its Usefulness and Problems.
Chujo S; Sugimoto M; Sasaki T; Matsui Y; Kato K; Ichio A; Miyata R; Matsubara H; Kondo M
J Clin Med; 2020 Sep; 9(9):. PubMed ID: 32887464
[TBL] [Abstract][Full Text] [Related]
18. Intravitreal Tissue Plasminogen Activator, Ranibizumab, and Gas Injection for Submacular Hemorrhage in Polypoidal Choroidal Vasculopathy.
Kitagawa Y; Shimada H; Mori R; Tanaka K; Yuzawa M
Ophthalmology; 2016 Jun; 123(6):1278-86. PubMed ID: 26949121
[TBL] [Abstract][Full Text] [Related]
19. Bevacizumab versus ranibizumab in the treatment of exudative age-related macular degeneration.
Gamulescu MA; Radeck V; Lustinger B; Fink B; Helbig H
Int Ophthalmol; 2010 Jun; 30(3):261-6. PubMed ID: 19633973
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of outer retinal tubulations in eyes switched from intravitreal ranibizumab to aflibercept for treatment of exudative age-related macular degeneration.
Massamba N; Dirani A; Butel N; Fardeau C; Bodaghi B; Ingram A; Lehoang P
Graefes Arch Clin Exp Ophthalmol; 2017 Jan; 255(1):61-67. PubMed ID: 27397583
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]